HeartBeam (NASDAQ: BEAT) is advancing technology designed to address a persistent challenge in cardiac care: pre-hospital delay. Many patients experiencing symptoms such as intermittent chest pain or palpitations do not seek medical attention promptly, and traditional electrocardiogram (ECG) testing is typically confined to clinical environments. This mismatch between symptom onset and diagnostic availability often leaves clinicians without critical data for timely decisions. The company's HeartBeam System aims to close this gap by transforming how ECG data are collected and used.
The HeartBeam System is a cable-free, high-fidelity ECG platform that captures the heart's electrical signals from three distinct directions for arrhythmia assessment. By collecting multidirectional signals, the system is intended to provide a more comprehensive representation of cardiac activity compared with conventional single-lead devices. The device is compact, about the size of a credit card, with embedded electrodes that allow patients to record ECG signals without adhesive patches or wires. This simplifies the user experience while maintaining data quality suitable for clinical interpretation.
A key feature is the system's ability to generate synthesized 12-lead ECG signals from its recordings, bringing clinical-grade data typically associated with hospital equipment into a portable format. The HeartBeam System is currently FDA cleared for arrhythmia assessment, and the company plans to submit for an indication expansion for heart attack detection in the future. The full article detailing this technology is available at https://ibn.fm/X6IEc.
HeartBeam holds 13 U.S. and 4 international issued patents related to its technology. The company's platform is designed for use in portable devices that can be used wherever the patient is, delivering actionable heart intelligence to physicians. This could allow for identification of cardiac health trends and acute conditions outside a medical facility, potentially redefining cardiac health management. For more information, visit www.HeartBeam.com.
The news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. Forward-looking statements in this article involve risks and uncertainties, and actual results may differ materially. These risks are detailed in the company's filings with the SEC, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The original release can be viewed at www.newmediawire.com.
